ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1299

Can Bone Marrow Lesions be Scored More Reliably and Responsively in Knee Osteoarthritis Using a Web-Based Overlay System (KIMRISS) Than By Standard MRI Osteoarthritis Knee Scoring (MOAKS)?  Data from the Osteoarthritis Initiative and a Prospective Trial of Adaluminab Therapy

Jacob Jaremko1, Mark Buller2, Dean Jeffery2, David McDougall3, Benjamin Smith2, Robert G Lambert1 and Walter Maksymowych4, 1Radiology, Radiology, University of Alberta, Edmonton, AB, Canada, 2Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, 3Radiology, University of Alberta, Edmonton, AB, Canada, 4Medicine, University of Alberta, Edmonton, AB, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Imaging, Knee, MRI and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Bone marrow lesions (BML) relate to pain and prognosis in knee osteoarthritis.  The Knee Inflammation MRI Scoring System (KIMRISS) offers simple template-assisted binary BML scoring via a web-based interface. We tested whether KIMRISS was more reliable and responsive to change than the commonly used MRI Osteoarthritis Knee Score (MOAKS) system, particularly for naïve readers.  

Methods:

The KIMRISS web-based overlay system separates the knee into multiple small regions, each scored 0 (no BML) or 1 (BML present).  The reader scrolls through sagittal fluid-sensitive MRI slices and mouse-clicks (or contacts a touch-screen) each region in which BML is present.  Scores are tabulated and exported automatically.  In contrast, MOAKS BML grading is performed in 9 larger knee regions based on the number of lesions present and percentages of the region containing edema and cystic change.

Exercise 1 assessed reliability, in observational data from the Osteoarthritis Initiative.  We had 40 subjects at baseline and 1 year follow-up (80 MRI).  Expert readings were performed by two radiologists (6 and 11 years experience) familiar with KIMRISS, and consensus score computed as the average of these readings. Two radiology residents naïve to KIMRISS and MOAKS reviewed a 55-slide presentation describing KIMRISS, three scored reference cases, and a published manuscript describing MOAKS.  These readers then scored the same data by KIMRISS and MOAKS.  All readers were blinded to scan time point (baseline vs. follow-up). 

Exercise 2 assessed responsiveness, using data from an open-label pilot study testing adalimumab (Humira) knee OA therapy. Two blinded experienced readers scored BML by MOAKS and KIMRISS at enrolment and 12 weeks post-therapy in all 16 patients (32 MRI).   

Reliability statistics were calculated using intra-class correlation coefficients (ICC), with differences significant at p<0.05 when the 95% confidence intervals of ICC did not overlap.  To assess responsiveness in Exercise 2, we computed standardized response means (SRM).

Results:

Subjects were primarily older adults (average 62 and 58 years for Exercises 1 and 2 respectively), and female (80% and 65%), with moderate OA (K-L grade 3 or 4 in 73% and 75%). 

In Exercise 1, reliability of KIMRISS and MOAKS was high and similar for baseline BML (ICC 0.89-0.98 vs 0.85-0.89).  However, changes in BML were significantly more reliably detected by KIMRISS than MOAKS, whether comparing expert readings (ICC 0.82 vs. 0.53) or comparing naïve readings to expert consensus (ICC 0.87-0.92 KIMRISS vs. 0.32-0.51 MOAKS). 

In Exercise 2, decrease in BML was visually obvious post treatment in most patients.  This decrease in BML was statistically significant when scored by KIMRISS (mean change from 37.3 to 29.8, SRM=-0.69, p=0.015), but not by MOAKS (6.25 to 6.06, SRM=-0.12, p=0.63). 

Conclusion:

Comparing two semi-quantitative MRI BML scoring systems, KIMRISS was more responsive to change in BML than MOAKS, and detected change with better reliability than MOAKS for expert and naïve readers.  KIMRISS scoring may be useful in observational and therapeutic trials for knee OA.


Disclosure: J. Jaremko, None; M. Buller, None; D. Jeffery, None; D. McDougall, None; B. Smith, None; R. G. Lambert, None; W. Maksymowych, AbbVie, Janssen, Pfizer, 2,AbbVie, Amgen, UCB, Pfizer, Merck, Janssen, Eli Lilly, Celgene, Synarc, Boehringer, 1.

To cite this abstract in AMA style:

Jaremko J, Buller M, Jeffery D, McDougall D, Smith B, Lambert RG, Maksymowych W. Can Bone Marrow Lesions be Scored More Reliably and Responsively in Knee Osteoarthritis Using a Web-Based Overlay System (KIMRISS) Than By Standard MRI Osteoarthritis Knee Scoring (MOAKS)?  Data from the Osteoarthritis Initiative and a Prospective Trial of Adaluminab Therapy [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/can-bone-marrow-lesions-be-scored-more-reliably-and-responsively-in-knee-osteoarthritis-using-a-web-based-overlay-system-kimriss-than-by-standard-mri-osteoarthritis-knee-scoring-moaks-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-bone-marrow-lesions-be-scored-more-reliably-and-responsively-in-knee-osteoarthritis-using-a-web-based-overlay-system-kimriss-than-by-standard-mri-osteoarthritis-knee-scoring-moaks-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology